# MTX-531

Source: https://onco.cc/drugs/mtx-531/  
OnCo record `mtx-531` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MTX-531 is an experimental small molecule from MEKanistic Therapeutics, in phase 1 trials for head and neck squamous cell carcinoma, endometrial cancer and HER2-negative metastatic breast cancer and other cancers.

## Summary

MTX-531 is a small molecule (oral) from MEKanistic Therapeutics. A computationally designed small molecule that inhibits both EGFR and PI3K; the company says PPAR-gamma agonist activity reduces the hyperglycaemia expected from PI3K inhibition. Its furthest stage is phase 1, for head and neck squamous cell carcinoma, endometrial cancer, HER2-negative metastatic breast cancer and RAS and BRAF wild-type metastatic colorectal cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT07874880 not yet recruiting (registry, first posted 15 Oct 2026). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: MTX-531
- Modality: Small molecule (oral)
- Mechanism: A computationally designed small molecule that inhibits both EGFR and PI3K; the company says PPAR-gamma agonist activity reduces the hyperglycaemia expected from PI3K inhibition.

## Sources

- MEKanistic Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07874880
- MEKanistic Therapeutics: mekanistic.com: https://www.mekanistic.com/pipeline.html
- MEKanistic Therapeutics: mekanistic.com: https://www.mekanistic.com/
- ClinicalTrials.gov: trials of MTX-531: https://clinicaltrials.gov/search?intr=MTX-531

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- companies: [MEKanistic Therapeutics](https://onco.cc/companies/mekanistic-therapeutics/)
- trials: [MTX-531-001 Phase 1 Study in Advanced Solid Tumors](https://onco.cc/trials/nct07874880/)

---
JSON: https://onco.cc/api/v1/entities/mtx-531.json